PubMed:11320058
Annnotations
Glycan-Motif
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 87-92 | https://glytoucan.org/Structures/Glycans/G01187XC | denotes | Le(x) |
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 87-92 | Glycan_Motif | denotes | Le(x) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G01187XC |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-104 | Sentence | denotes | N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. |
| TextSentencer_T2 | 105-255 | Sentence | denotes | Cobra venom factor (CVF), a nontoxic, complement-activating glycoprotein in cobra venom, is a functional analog of mammalian complement component C3b. |
| TextSentencer_T3 | 256-417 | Sentence | denotes | The carbohydrate moiety of CVF consists exclusively of N-linked oligosaccharides with terminal alpha1-3-linked galactosyl residues, which are antigenic in human. |
| TextSentencer_T4 | 418-527 | Sentence | denotes | CVF has potential for several medical applications, including targeted cell killing and complement depletion. |
| TextSentencer_T5 | 528-606 | Sentence | denotes | Here, we report a detailed structural analysis of the oligosaccharides of CVF. |
| TextSentencer_T6 | 607-807 | Sentence | denotes | The structures of the oligosaccharides were determined by lectin affinity chromatography, antibody affinity blotting, compositional and methylation analyses, and high-resolution (1)H-NMR spectroscopy. |
| TextSentencer_T7 | 808-995 | Sentence | denotes | Approximately 80% of the oligosaccharides are diantennary complex-type, approximately 12% are tri- and tetra-antennary complex-type, and approximately 8% are oligomannose type structures. |
| TextSentencer_T8 | 996-1202 | Sentence | denotes | The majority of the complex-type oligosaccharides terminate in Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1, a unique carbohydrate structural feature abundantly present in the glycoproteins of cobra venom. |
| T1 | 0-104 | Sentence | denotes | N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. |
| T2 | 105-255 | Sentence | denotes | Cobra venom factor (CVF), a nontoxic, complement-activating glycoprotein in cobra venom, is a functional analog of mammalian complement component C3b. |
| T3 | 256-417 | Sentence | denotes | The carbohydrate moiety of CVF consists exclusively of N-linked oligosaccharides with terminal alpha1-3-linked galactosyl residues, which are antigenic in human. |
| T4 | 418-527 | Sentence | denotes | CVF has potential for several medical applications, including targeted cell killing and complement depletion. |
| T5 | 528-606 | Sentence | denotes | Here, we report a detailed structural analysis of the oligosaccharides of CVF. |
| T6 | 607-807 | Sentence | denotes | The structures of the oligosaccharides were determined by lectin affinity chromatography, antibody affinity blotting, compositional and methylation analyses, and high-resolution (1)H-NMR spectroscopy. |
| T7 | 808-995 | Sentence | denotes | Approximately 80% of the oligosaccharides are diantennary complex-type, approximately 12% are tri- and tetra-antennary complex-type, and approximately 8% are oligomannose type structures. |
| T8 | 996-1202 | Sentence | denotes | The majority of the complex-type oligosaccharides terminate in Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1, a unique carbohydrate structural feature abundantly present in the glycoproteins of cobra venom. |
| T1 | 0-104 | Sentence | denotes | N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. |
| T2 | 105-255 | Sentence | denotes | Cobra venom factor (CVF), a nontoxic, complement-activating glycoprotein in cobra venom, is a functional analog of mammalian complement component C3b. |
| T3 | 256-417 | Sentence | denotes | The carbohydrate moiety of CVF consists exclusively of N-linked oligosaccharides with terminal alpha1-3-linked galactosyl residues, which are antigenic in human. |
| T4 | 418-527 | Sentence | denotes | CVF has potential for several medical applications, including targeted cell killing and complement depletion. |
| T5 | 528-606 | Sentence | denotes | Here, we report a detailed structural analysis of the oligosaccharides of CVF. |
| T6 | 607-807 | Sentence | denotes | The structures of the oligosaccharides were determined by lectin affinity chromatography, antibody affinity blotting, compositional and methylation analyses, and high-resolution (1)H-NMR spectroscopy. |
| T7 | 808-995 | Sentence | denotes | Approximately 80% of the oligosaccharides are diantennary complex-type, approximately 12% are tri- and tetra-antennary complex-type, and approximately 8% are oligomannose type structures. |
| T8 | 996-1202 | Sentence | denotes | The majority of the complex-type oligosaccharides terminate in Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1, a unique carbohydrate structural feature abundantly present in the glycoproteins of cobra venom. |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 87-92 | https://glytoucan.org/Structures/Glycans/G01187XC | denotes | Le(x) |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 9-25 | FMAID:196731 | denotes | oligosaccharides |
| _T2 | 9-25 | FMAID:82742 | denotes | oligosaccharides |
| _T3 | 165-177 | FMAID:62925 | denotes | glycoprotein |
| _T4 | 165-177 | FMAID:167256 | denotes | glycoprotein |
| _T5 | 260-272 | FMAID:82737 | denotes | carbohydrate |
| _T6 | 260-272 | FMAID:197276 | denotes | carbohydrate |
| _T7 | 320-336 | FMAID:82742 | denotes | oligosaccharides |
| _T8 | 320-336 | FMAID:196731 | denotes | oligosaccharides |
| _T9 | 582-598 | FMAID:196731 | denotes | oligosaccharides |
| _T10 | 582-598 | FMAID:82742 | denotes | oligosaccharides |
| _T11 | 629-645 | FMAID:196731 | denotes | oligosaccharides |
| _T12 | 629-645 | FMAID:82742 | denotes | oligosaccharides |
| _T13 | 697-705 | FMAID:167180 | denotes | antibody |
| _T14 | 725-738 | FMAID:50603 | denotes | compositional |
| _T15 | 725-738 | FMAID:146309 | denotes | compositional |
| _T16 | 833-849 | FMAID:82742 | denotes | oligosaccharides |
| _T17 | 833-849 | FMAID:196731 | denotes | oligosaccharides |
| _T18 | 1029-1045 | FMAID:82742 | denotes | oligosaccharides |
| _T19 | 1029-1045 | FMAID:196731 | denotes | oligosaccharides |
| _T20 | 1115-1127 | FMAID:197276 | denotes | carbohydrate |
| _T21 | 1115-1127 | FMAID:82737 | denotes | carbohydrate |
| _T22 | 1173-1186 | FMAID:62925 | denotes | glycoproteins |
| _T23 | 1173-1186 | FMAID:167256 | denotes | glycoproteins |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 911-916 | http://purl.bioontology.org/ontology/NCBITAXON/85284 | denotes | tetra |
| T2 | 911-916 | http://purl.bioontology.org/ontology/NCBITAXON/1310384 | denotes | tetra |
| T3 | 917-926 | http://purl.bioontology.org/ontology/NCBITAXON/293542 | denotes | antennary |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 143-164 | http://purl.obolibrary.org/obo/GO_0006956 | denotes | complement-activating |
| T2 | 489-501 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | cell killing |
| T3 | 743-754 | http://purl.obolibrary.org/obo/GO_0032259 | denotes | methylation |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 697-705 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
GO-CC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 489-493 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 35-40 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| T2 | 111-116 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| T3 | 187-192 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| T4 | 1196-1201 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
EDAM-topics
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 260-272 | http://edamontology.org/topic_0152 | denotes | carbohydrate |
| T2 | 342-350 | http://edamontology.org/topic_0749 | denotes | terminal |
| T3 | 398-407 | http://edamontology.org/topic_2830 | denotes | antigenic |
| T4 | 411-416 | http://edamontology.org/topic_2815 | denotes | human |
| T5 | 480-488 | http://edamontology.org/topic_0154 | denotes | targeted |
| T6 | 555-574 | http://edamontology.org/topic_0081 | denotes | structural analysis |
| T7 | 790-793 | http://edamontology.org/topic_0593 | denotes | NMR |
| T8 | 790-806 | http://edamontology.org/topic_0593 | denotes | NMR spectroscopy |
| T9 | 794-806 | http://edamontology.org/topic_0593 | denotes | spectroscopy |
| T10 | 1046-1055 | http://edamontology.org/topic_0749 | denotes | terminate |
| T11 | 1115-1127 | http://edamontology.org/topic_0152 | denotes | carbohydrate |
EDAM-DFO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 93-103 | http://edamontology.org/data_0883 | denotes | structures |
| T2 | 378-386 | http://edamontology.org/data_1756 | denotes | residues |
| T3 | 537-543 | http://edamontology.org/data_2048 | denotes | report |
| T4 | 555-565 | http://edamontology.org/data_0883 | denotes | structural |
| T5 | 555-574 | http://edamontology.org/operation_2480 | denotes | structural analysis |
| T6 | 566-574 | http://edamontology.org/operation_2945 | denotes | analysis |
| T7 | 611-621 | http://edamontology.org/data_0883 | denotes | structures |
| T8 | 743-763 | http://edamontology.org/operation_3204 | denotes | methylation analyses |
| T9 | 984-994 | http://edamontology.org/data_0883 | denotes | structures |
| T10 | 1115-1138 | http://edamontology.org/data_1462 | denotes | carbohydrate structural |
| T11 | 1128-1138 | http://edamontology.org/data_0883 | denotes | structural |
| T12 | 1139-1146 | http://edamontology.org/data_1255 | denotes | feature |
GlyTouCan-IUPAC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| GlycanIUPAC_T1 | 902-905 | "http://rdf.glycoinfo.org/glycan/G44384WF" | denotes | tri |
| GlycanIUPAC_T2 | 902-905 | "http://rdf.glycoinfo.org/glycan/G37452RG" | denotes | tri |
| GlycanIUPAC_T3 | 902-905 | "http://rdf.glycoinfo.org/glycan/G56296FC" | denotes | tri |
| GlycanIUPAC_T4 | 902-905 | "http://rdf.glycoinfo.org/glycan/G44877OG" | denotes | tri |
| GlycanIUPAC_T5 | 902-905 | "http://rdf.glycoinfo.org/glycan/G22627HB" | denotes | tri |
| GlycanIUPAC_T6 | 902-905 | "http://rdf.glycoinfo.org/glycan/G76069IP" | denotes | tri |
| GlycanIUPAC_T7 | 902-905 | "http://rdf.glycoinfo.org/glycan/G77301LL" | denotes | tri |
| GlycanIUPAC_T8 | 902-905 | "http://rdf.glycoinfo.org/glycan/G92446EV" | denotes | tri |
| GlycanIUPAC_T9 | 902-905 | "http://rdf.glycoinfo.org/glycan/G93798MG" | denotes | tri |
| GlycanIUPAC_T10 | 902-905 | "http://rdf.glycoinfo.org/glycan/G19180VS" | denotes | tri |
| GlycanIUPAC_T11 | 902-905 | "http://rdf.glycoinfo.org/glycan/G00261CT" | denotes | tri |
| GlycanIUPAC_T12 | 902-905 | "http://rdf.glycoinfo.org/glycan/G23925MM" | denotes | tri |
| GlycanIUPAC_T13 | 902-905 | "http://rdf.glycoinfo.org/glycan/G27176LA" | denotes | tri |
| GlycanIUPAC_T14 | 902-905 | "http://rdf.glycoinfo.org/glycan/G76226NF" | denotes | tri |
| GlycanIUPAC_T15 | 902-905 | "http://rdf.glycoinfo.org/glycan/G80006GG" | denotes | tri |
| GlycanIUPAC_T16 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99968MY" | denotes | tri |
| GlycanIUPAC_T17 | 902-905 | "http://rdf.glycoinfo.org/glycan/G67393MB" | denotes | tri |
| GlycanIUPAC_T18 | 902-905 | "http://rdf.glycoinfo.org/glycan/G09037VU" | denotes | tri |
| GlycanIUPAC_T19 | 902-905 | "http://rdf.glycoinfo.org/glycan/G19508PX" | denotes | tri |
| GlycanIUPAC_T20 | 902-905 | "http://rdf.glycoinfo.org/glycan/G40619ZS" | denotes | tri |
| GlycanIUPAC_T21 | 902-905 | "http://rdf.glycoinfo.org/glycan/G19507SX" | denotes | tri |
| GlycanIUPAC_T22 | 902-905 | "http://rdf.glycoinfo.org/glycan/G50874XT" | denotes | tri |
| GlycanIUPAC_T23 | 902-905 | "http://rdf.glycoinfo.org/glycan/G60561GL" | denotes | tri |
| GlycanIUPAC_T24 | 902-905 | "http://rdf.glycoinfo.org/glycan/G98788DE" | denotes | tri |
| GlycanIUPAC_T25 | 902-905 | "http://rdf.glycoinfo.org/glycan/G85696MX" | denotes | tri |
| GlycanIUPAC_T26 | 902-905 | "http://rdf.glycoinfo.org/glycan/G82652IN" | denotes | tri |
| GlycanIUPAC_T27 | 902-905 | "http://rdf.glycoinfo.org/glycan/G95603AK" | denotes | tri |
| GlycanIUPAC_T28 | 902-905 | "http://rdf.glycoinfo.org/glycan/G87993NJ" | denotes | tri |
| GlycanIUPAC_T29 | 902-905 | "http://rdf.glycoinfo.org/glycan/G85533KK" | denotes | tri |
| GlycanIUPAC_T30 | 902-905 | "http://rdf.glycoinfo.org/glycan/G78142NX" | denotes | tri |
| GlycanIUPAC_T31 | 902-905 | "http://rdf.glycoinfo.org/glycan/G94944YR" | denotes | tri |
| GlycanIUPAC_T32 | 902-905 | "http://rdf.glycoinfo.org/glycan/G60875EM" | denotes | tri |
| GlycanIUPAC_T33 | 902-905 | "http://rdf.glycoinfo.org/glycan/G58390SD" | denotes | tri |
| GlycanIUPAC_T34 | 902-905 | "http://rdf.glycoinfo.org/glycan/G46314WZ" | denotes | tri |
| GlycanIUPAC_T35 | 902-905 | "http://rdf.glycoinfo.org/glycan/G35012MY" | denotes | tri |
| GlycanIUPAC_T36 | 902-905 | "http://rdf.glycoinfo.org/glycan/G11847VZ" | denotes | tri |
| GlycanIUPAC_T37 | 902-905 | "http://rdf.glycoinfo.org/glycan/G91662AB" | denotes | tri |
| GlycanIUPAC_T38 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99771WN" | denotes | tri |
| GlycanIUPAC_T39 | 902-905 | "http://rdf.glycoinfo.org/glycan/G92389SI" | denotes | tri |
| GlycanIUPAC_T40 | 902-905 | "http://rdf.glycoinfo.org/glycan/G40437FC" | denotes | tri |
| GlycanIUPAC_T41 | 902-905 | "http://rdf.glycoinfo.org/glycan/G00509WV" | denotes | tri |
| GlycanIUPAC_T42 | 902-905 | "http://rdf.glycoinfo.org/glycan/G36565LB" | denotes | tri |
| GlycanIUPAC_T43 | 902-905 | "http://rdf.glycoinfo.org/glycan/G50335BH" | denotes | tri |
| GlycanIUPAC_T44 | 902-905 | "http://rdf.glycoinfo.org/glycan/G87946UV" | denotes | tri |
| GlycanIUPAC_T45 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99103VB" | denotes | tri |
| GlycanIUPAC_T46 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99530XJ" | denotes | tri |
| GlycanIUPAC_T47 | 902-905 | "http://rdf.glycoinfo.org/glycan/G64132OC" | denotes | tri |
| GlycanIUPAC_T48 | 902-905 | "http://rdf.glycoinfo.org/glycan/G96071SL" | denotes | tri |
| GlycanIUPAC_T49 | 902-905 | "http://rdf.glycoinfo.org/glycan/G11932TO" | denotes | tri |
| GlycanIUPAC_T50 | 902-905 | "http://rdf.glycoinfo.org/glycan/G71952HE" | denotes | tri |
| GlycanIUPAC_T51 | 902-905 | "http://rdf.glycoinfo.org/glycan/G40960ZM" | denotes | tri |
| GlycanIUPAC_T52 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99023OP" | denotes | tri |
| GlycanIUPAC_T53 | 902-905 | "http://rdf.glycoinfo.org/glycan/G75940FW" | denotes | tri |
| GlycanIUPAC_T54 | 902-905 | "http://rdf.glycoinfo.org/glycan/G05449DN" | denotes | tri |
| GlycanIUPAC_T55 | 902-905 | "http://rdf.glycoinfo.org/glycan/G12045NX" | denotes | tri |
| GlycanIUPAC_T56 | 902-905 | "http://rdf.glycoinfo.org/glycan/G23531GF" | denotes | tri |
| GlycanIUPAC_T57 | 902-905 | "http://rdf.glycoinfo.org/glycan/G83439GF" | denotes | tri |
| GlycanIUPAC_T58 | 902-905 | "http://rdf.glycoinfo.org/glycan/G38120XA" | denotes | tri |
| GlycanIUPAC_T59 | 902-905 | "http://rdf.glycoinfo.org/glycan/G09257XC" | denotes | tri |
| GlycanIUPAC_T60 | 902-905 | "http://rdf.glycoinfo.org/glycan/G67867AY" | denotes | tri |
| GlycanIUPAC_T61 | 902-905 | "http://rdf.glycoinfo.org/glycan/G70826LI" | denotes | tri |
| GlycanIUPAC_T62 | 902-905 | "http://rdf.glycoinfo.org/glycan/G01893YT" | denotes | tri |
| GlycanIUPAC_T63 | 902-905 | "http://rdf.glycoinfo.org/glycan/G57032UK" | denotes | tri |
| GlycanIUPAC_T64 | 902-905 | "http://rdf.glycoinfo.org/glycan/G82566JW" | denotes | tri |
| GlycanIUPAC_T65 | 902-905 | "http://rdf.glycoinfo.org/glycan/G03647LB" | denotes | tri |
| GlycanIUPAC_T66 | 902-905 | "http://rdf.glycoinfo.org/glycan/G30298YA" | denotes | tri |
| GlycanIUPAC_T67 | 902-905 | "http://rdf.glycoinfo.org/glycan/G12237BJ" | denotes | tri |
| GlycanIUPAC_T68 | 902-905 | "http://rdf.glycoinfo.org/glycan/G35293BQ" | denotes | tri |
| GlycanIUPAC_T69 | 902-905 | "http://rdf.glycoinfo.org/glycan/G56939XC" | denotes | tri |
| GlycanIUPAC_T70 | 902-905 | "http://rdf.glycoinfo.org/glycan/G57481VS" | denotes | tri |
| GlycanIUPAC_T71 | 902-905 | "http://rdf.glycoinfo.org/glycan/G12760VJ" | denotes | tri |
| GlycanIUPAC_T72 | 902-905 | "http://rdf.glycoinfo.org/glycan/G78749LG" | denotes | tri |
| GlycanIUPAC_T73 | 902-905 | "http://rdf.glycoinfo.org/glycan/G18179BX" | denotes | tri |
| GlycanIUPAC_T74 | 902-905 | "http://rdf.glycoinfo.org/glycan/G97803IP" | denotes | tri |
| GlycanIUPAC_T75 | 902-905 | "http://rdf.glycoinfo.org/glycan/G98770PI" | denotes | tri |
| GlycanIUPAC_T76 | 902-905 | "http://rdf.glycoinfo.org/glycan/G48944LU" | denotes | tri |
| GlycanIUPAC_T77 | 902-905 | "http://rdf.glycoinfo.org/glycan/G68361HD" | denotes | tri |
| GlycanIUPAC_T78 | 902-905 | "http://rdf.glycoinfo.org/glycan/G57043GW" | denotes | tri |
| GlycanIUPAC_T79 | 902-905 | "http://rdf.glycoinfo.org/glycan/G68666JO" | denotes | tri |
| GlycanIUPAC_T80 | 902-905 | "http://rdf.glycoinfo.org/glycan/G52284HH" | denotes | tri |
| GlycanIUPAC_T81 | 902-905 | "http://rdf.glycoinfo.org/glycan/G48271RR" | denotes | tri |
| GlycanIUPAC_T82 | 902-905 | "http://rdf.glycoinfo.org/glycan/G28222XB" | denotes | tri |
| GlycanIUPAC_T83 | 902-905 | "http://rdf.glycoinfo.org/glycan/G69666WN" | denotes | tri |
| GlycanIUPAC_T84 | 902-905 | "http://rdf.glycoinfo.org/glycan/G00846QB" | denotes | tri |
| GlycanIUPAC_T85 | 902-905 | "http://rdf.glycoinfo.org/glycan/G34497XL" | denotes | tri |
| GlycanIUPAC_T86 | 902-905 | "http://rdf.glycoinfo.org/glycan/G83093ZM" | denotes | tri |
| GlycanIUPAC_T87 | 902-905 | "http://rdf.glycoinfo.org/glycan/G07756TT" | denotes | tri |
| GlycanIUPAC_T88 | 902-905 | "http://rdf.glycoinfo.org/glycan/G26740FE" | denotes | tri |
| GlycanIUPAC_T89 | 902-905 | "http://rdf.glycoinfo.org/glycan/G32930YQ" | denotes | tri |
| GlycanIUPAC_T90 | 902-905 | "http://rdf.glycoinfo.org/glycan/G75215RK" | denotes | tri |
| GlycanIUPAC_T91 | 902-905 | "http://rdf.glycoinfo.org/glycan/G98272YB" | denotes | tri |
| GlycanIUPAC_T92 | 902-905 | "http://rdf.glycoinfo.org/glycan/G71155WF" | denotes | tri |
| GlycanIUPAC_T93 | 902-905 | "http://rdf.glycoinfo.org/glycan/G56744IY" | denotes | tri |
| GlycanIUPAC_T94 | 902-905 | "http://rdf.glycoinfo.org/glycan/G38394RH" | denotes | tri |
| GlycanIUPAC_T95 | 902-905 | "http://rdf.glycoinfo.org/glycan/G11815AV" | denotes | tri |
| GlycanIUPAC_T96 | 902-905 | "http://rdf.glycoinfo.org/glycan/G62676XB" | denotes | tri |
| GlycanIUPAC_T97 | 902-905 | "http://rdf.glycoinfo.org/glycan/G96377XW" | denotes | tri |
| GlycanIUPAC_T98 | 902-905 | "http://rdf.glycoinfo.org/glycan/G99347BR" | denotes | tri |
| GlycanIUPAC_T99 | 902-905 | "http://rdf.glycoinfo.org/glycan/G70803WR" | denotes | tri |
| GlycanIUPAC_T100 | 902-905 | "http://rdf.glycoinfo.org/glycan/G88778DU" | denotes | tri |
| GlycanIUPAC_T101 | 902-905 | "http://rdf.glycoinfo.org/glycan/G07971EH" | denotes | tri |
| GlycanIUPAC_T102 | 902-905 | "http://rdf.glycoinfo.org/glycan/G95272JN" | denotes | tri |
| GlycanIUPAC_T103 | 902-905 | "http://rdf.glycoinfo.org/glycan/G55109ZG" | denotes | tri |
| GlycanIUPAC_T104 | 902-905 | "http://rdf.glycoinfo.org/glycan/G71585SL" | denotes | tri |
| GlycanIUPAC_T105 | 902-905 | "http://rdf.glycoinfo.org/glycan/G07197CP" | denotes | tri |
| GlycanIUPAC_T106 | 902-905 | "http://rdf.glycoinfo.org/glycan/G17730NT" | denotes | tri |
| GlycanIUPAC_T107 | 902-905 | "http://rdf.glycoinfo.org/glycan/G34903LH" | denotes | tri |
| GlycanIUPAC_T108 | 902-905 | "http://rdf.glycoinfo.org/glycan/G65660GA" | denotes | tri |
| GlycanIUPAC_T109 | 902-905 | "http://rdf.glycoinfo.org/glycan/G48172IK" | denotes | tri |
| GlycanIUPAC_T110 | 902-905 | "http://rdf.glycoinfo.org/glycan/G20725CN" | denotes | tri |
| GlycanIUPAC_T111 | 902-905 | "http://rdf.glycoinfo.org/glycan/G50853HE" | denotes | tri |
| GlycanIUPAC_T112 | 902-905 | "http://rdf.glycoinfo.org/glycan/G18401GJ" | denotes | tri |
| GlycanIUPAC_T113 | 902-905 | "http://rdf.glycoinfo.org/glycan/G89755ME" | denotes | tri |
| GlycanIUPAC_T114 | 902-905 | "http://rdf.glycoinfo.org/glycan/G58581FW" | denotes | tri |
| GlycanIUPAC_T115 | 902-905 | "http://rdf.glycoinfo.org/glycan/G84356OA" | denotes | tri |
| GlycanIUPAC_T116 | 902-905 | "http://rdf.glycoinfo.org/glycan/G48553NO" | denotes | tri |
| GlycanIUPAC_T117 | 902-905 | "http://rdf.glycoinfo.org/glycan/G86886IB" | denotes | tri |
| GlycanIUPAC_T118 | 902-905 | "http://rdf.glycoinfo.org/glycan/G22655ST" | denotes | tri |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 35-40 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| PD-UBERON-AE-B_T2 | 111-116 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| PD-UBERON-AE-B_T3 | 187-192 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
| PD-UBERON-AE-B_T4 | 1196-1201 | http://purl.obolibrary.org/obo/UBERON_0007113 | denotes | venom |
Lectin-Jamboree
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 665-671 | lectin | denotes | lectin |
Lectin-Jamboree-Sentence
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-104 | Sentence | denotes | N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. |
| T2 | 105-255 | Sentence | denotes | Cobra venom factor (CVF), a nontoxic, complement-activating glycoprotein in cobra venom, is a functional analog of mammalian complement component C3b. |
| T3 | 256-417 | Sentence | denotes | The carbohydrate moiety of CVF consists exclusively of N-linked oligosaccharides with terminal alpha1-3-linked galactosyl residues, which are antigenic in human. |
| T4 | 418-527 | Sentence | denotes | CVF has potential for several medical applications, including targeted cell killing and complement depletion. |
| T5 | 528-606 | Sentence | denotes | Here, we report a detailed structural analysis of the oligosaccharides of CVF. |
| T6 | 607-807 | Sentence | denotes | The structures of the oligosaccharides were determined by lectin affinity chromatography, antibody affinity blotting, compositional and methylation analyses, and high-resolution (1)H-NMR spectroscopy. |
| T7 | 808-995 | Sentence | denotes | Approximately 80% of the oligosaccharides are diantennary complex-type, approximately 12% are tri- and tetra-antennary complex-type, and approximately 8% are oligomannose type structures. |
| T8 | 996-1202 | Sentence | denotes | The majority of the complex-type oligosaccharides terminate in Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1, a unique carbohydrate structural feature abundantly present in the glycoproteins of cobra venom. |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 411-416 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 35-40 | Body_part | denotes | venom | http://purl.obolibrary.org/obo/UBERON_0007113 |
| T2 | 111-116 | Body_part | denotes | venom | http://purl.obolibrary.org/obo/UBERON_0007113 |
| T3 | 187-192 | Body_part | denotes | venom | http://purl.obolibrary.org/obo/UBERON_0007113 |
| T4 | 1196-1201 | Body_part | denotes | venom | http://purl.obolibrary.org/obo/UBERON_0007113 |